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Abstract A growing body of evidence implicates the
endocannabinoid (eCB) system in the pathophysiology
of depression. The aim of this study was to investigate the influ-
ence of changes in the eCB system, such as levels of
neuromodulators, eCB synthesizing and degrading enzymes,
and cannabinoid (CB) receptors, in different brain structures in
animal models of depression using behavioral and biochemical
analyses. Both models used, i.e., bulbectomized (OBX) and
Wistar Kyoto (WKY) rats, were characterized at the behavioral
level by increased immobility time. In theOBX rats, anandamide
(AEA) levels were decreased in the prefrontal cortex, hippocam-
pus, and striatum and increased in the nucleus accumbens, while
2-arachidonoylglycerol (2-AG) levels were increased in the pre-
frontal cortex and decreased in the nucleus accumbens with par-
allel changes in the expression of eCB metabolizing enzymes in
several structures. It was also observed that CB1 receptor expres-
sion decreased in the hippocampus, dorsal striatum, and nucleus
accumbens, and CB2 receptor expression decreased in the pre-
frontal cortex and hippocampus. In WKY rats, the levels of
eCBs were reduced in the prefrontal cortex (2-AG) and dorsal
striatum (AEA) and increased in the prefrontal cortex (AEA)
with different changes in the expression of eCB metabolizing
enzymes, while the CB1 receptor density was increased in sev-
eral brain regions. These findings suggest that dysregulation in
the eCB system is implicated in the pathogenesis of depression,
although neurochemical changes were linked to the particular
brain structure and the factor inducing depression (surgical re-
moval of the olfactory bulbs vs. genetic modulation).
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Introduction
At present, depression is one of the most common psychiatric
disorders, but its pharmacotherapy and pathophysiology are
still unclear. The etiology of depression is multifactorial and
related to disturbed monoaminergic transmission, changes in
receptor function, dysregulation of the stress axis, a reduction
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of neurogenesis, activated inflammatory processes, or in-
creased oxidative stress (Moniczewski et al. 2015; Smaga
et al. 2015). Recent observations strongly support the involve-
ment of the endocannabinoid (eCB) system in the pathogene-
sis of depression. In preclinical studies, genetic deletion of the
cannabinoid (CB1) receptor or the CB1 receptor blockade re-
sulted in depressive-like behavior (Sanchis-Segura et al. 2004;
Aso et al. 2008; Steiner et al. 2008; Mikics et al. 2009). On the
other hand, the facilitation of eCB signaling exerts
antidepressant-like behavioral responses in rodents, which
were observed after: anandamide (AEA) administration
(Umathe et al. 2011), AEA uptake inhibition (Hill and
Gorzalka 2005; Adamczyk et al. 2008; Mannucci et al.
2011; Umathe et al. 2011), eCB degrading enzyme inhibition
(Gobbi et al. 2005; Adamczyk et al. 2008), or by direct CB1
agonists (Bambico et al. 2007; Haring et al. 2013; Smaga et al.
2014b). Moreover, reduction of eCB signaling was linked to
depressive-like behavior in several models of depression (Hill
et al. 2005, 2008a; Eisenstein et al. 2010; Dubreucq et al.
2012; Vinod et al. 2012). In a human study, administration
of a CB1 antagonist (rimonabant) (Christensen et al. 2007;
Horder et al. 2009) for treatment of obesity resulted in the
development of depression and anhedonia. Additionally, aug-
mentation of eCB signaling evoked different changes impli-
cated in antidepressant effects, such as modulation of neuro-
transmitter release, regulation of the stress axis, promotion of
neurogenesis, and normalization of the excitation state
(Smaga et al. 2014a, b).
The aim of the present study was to perform a complex
analysis to the eCB system (i.e., endogenous ligands, en-
zymes involved in eCB metabolism, and CB receptors) in
the pathogenesis of depression by using valid animal models
of depression: Wistar Kyoto (WKY) rats and bulbectomized
(OBX) animals. We focused on determining whether the
levels of eCBs (i.e., AEA and 2-arachidonoylglycerol (2-
AG)), the expression of the eCB synthesizing enzymes (N-
acyl phosphatidylethanolamine phospholipase D (NAPE-
PLD) and diacylglycerol lipase α (DAGLα)), or eCB
degrading enzymes (fatty acid amide hydrolase (FAAH) and
monoacylglycerol lipase (MAGL)) were altered in particular
models of depression. Finally, we measured the expression of
CB receptors and CB1 receptor density. The olfactory
bulbectomy is used as a model of depression induced by an
injury and is characterized by all of the proper criteria of
validity (face, construct, and predictive) that demonstrate a
good clinical picture of depression (Abelaira et al. 2013).
On the other hand, WKY rats are an example of a genetic
model of depression and are characterized by hyperactive
responses to stress with dysregulation of the hypothalamic-
pituitary-adrenal (HPA) axis. Both of these models demon-
strated behavioral, biochemical, and physiological abnormal-
ities reminiscent of depressive-like symptom (Will et al.
2003; Yuan and Slotnick 2014).
Experimental Procedures
Animals
The experiments were performed on male Wistar and WKY
rats (Charles River, Germany) weighing 280–300 g (approx-
imately 8–9 weeks old). The animals were kept on a normal
day-night cycle at 22 ± 2 °C with access to food and water ad
libitum. All experiments were carried out in accordance with
the EU directive 2010/63/EU and with approval of the
Bioethics Commission as compliant with the Polish Law (21
August 1997). There were 6–8 animals per group.
Olfactory Bulbectomy
During anesthesia (ketamine hydrochloride and xylazine mix-
ture in 3:1 v/v, im), bilateral olfactory bulbectomy was per-
formed onWistar rats. Metoxicam (0.05 mg/kg, sc) was given
as an analgesic and anti-inflammatory drug 60 min before the
surgery and for 2 days after the surgery. Two burr holes were
drilled on either side of the skull (taking care not to damage
the prefrontal cortex), 2 mm in diameter, 8 mm anterior to the
bregma, and 2 mm from the midline of the frontal bone over-
lying the olfactory bulbs (coordinates were taken from the Rat
Brain Atlas, Paxinos and Watson 1998). The olfactory bulbs
were removed by suction, and the burr holes were filled with a
hemostatic sponge to control bleeding. The skin was closed.
Animals receiving sham (SHAM) surgery underwent a similar
procedure but did not have their olfactory bulbs removed.
During the 14-day recovery, the animals were handled daily
by the experimenter to eliminate any aggressiveness that
would otherwise develop (Leonard and Tuite 1981; Smaga
et al. 2012). After the behavioral procedures, the OBX rats
were sacrificed through decapitation, and their brains were
rapidly removed and examined for signs of cortical damage
or incomplete removal of the olfactory bulbs. Such animals
were excluded from the data analysis.
Behavioral Tests
Locomotor Activity
Open field locomotor activity was recorded individually for
each animal in Opto-Varimex cages (Columbus Instruments,
Columbus, OH, USA) linked on-line to a compatible IBMPC.
Each cage (43 × 44 cm) was equipped with 15 infrared emit-
ters located on the x and y axes, 3 cm from the floor and with
the same number of receivers on the opposite walls of the
cage. The rats’ behavior was analyzed using Auto-Track soft-
ware (Columbus Instruments, Columbus, OH, USA).
Locomotor activity was defined as a breakage of three con-
secutive photobeams. Locomotor activity was defined as
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horizontal activity and presented as distance traveled in centi-
meter during 30-min trial (with 5-min intervals).
Forced Swimming Test (FST)
On the first day of the forced swim (i.e., pre-test), the rats were
placed individually in a cylinder (50 cm high × 23 cm in
diameter) filled to a 30-cm depth with water (25 ± 1 °C) for
15 min; they were then removed from the water, dried with
towels, placed in a warmer enclosure for 15 min, and were
then returned to their home cages, as described previously
(Frankowska et al. 2010). The cylinders were emptied and
cleaned between rats. Twenty-four hours following the first
exposure, the rats were tested for 5 min (300 s) under identical
conditions. Test sessions were scored by two observers un-
aware of the treatment condition, and the immobility time
was measured. A rat was considered to be immobile if it was
only making movements necessary to keep its head above
water.
Tissue Isolation
For biochemical analysis, experimental-naïve rats (WKY,
OBX, and corresponding controls) were sacrificed through
decapitation, and their brains were rapidly removed.
Selected brain structures (i.e., the prefrontal cortex, frontal
cortex, hippocampus, dorsal striatum, nucleus accumbens,
and cerebellum) were isolated using brain matrix according
to The Rat Brain Atlas (Paxinos and Watson 1998), immedi-
ately frozen on dry ice and stored at −80 °C for liquid chro-
matography tandem mass spectrometry (LC-MS/MS) and
Western blot analysis. Separate groups of animals were used
for autoradiography; their brains were rapidly dissected, fro-
zen by dry-ice bath using heptane, and were later stored at
−80 °C until sectioned.
Biochemical Analysis
LC-MS/MS
ReagentsAll chemical solvents and standards were of analyt-
ical grade. Standards of AEA and 2-AG were obtained from
Tocris (Bristol, United Kingdom), AEA-d4 and 2-AG-d5 from
Cayman Chemical (USA), acetonitrile and chloroform from
Merck (Darmstadt, Germany), and methanol and formic acid
from POCh (Katowice, Poland). Standard stock solutions
were prepared in ethanol (AEA and AEA-d4) or acetonitrile
(2-AG and 2-AG-d5). All stock solutions were stored at
−80 °C. Further dilutions were carried out appropriately in
acetonitrile.
Lipid Extraction from Brain Tissue The brain tissues were
weighed and subjected to eCB extraction. Extraction was
carried out by the modified methods of isolation of lipid com-
pounds, as described previously (Bystrowska et al. 2014b).
Tissues were homogenized using a sonicator (UP50H,
Hielscher) in the ice-cold mixture of methanol and chloroform
(1:2, v/v) in the proportion of 10 mg of wet tissue to 150 μl of
solvent to quench any possible enzymatic reaction that may
interfere with the analysis. Next, 150 μl of homogenate were
mixed with 2 μl of internal standard (AEA-d4, concentration
10 μg/ml; 2-AG-d5, concentration 100 μg/ml), 250 μl of
formic acid (pH 3.0; 0.2M), and 1500μl of extractionmixture
(methanol:chloroform 1:2, v/v). The internal standard indi-
cates analyte loss during sample work-up. Afterward, samples
were vortexed for 30 s and centrifuged for 10 min at
2000 rpm. Organic phases were collected and dried under a
stream of nitrogen at 40 °C. The residue was dissolved in
40 μl of acetonitrile, and 10 μl of the reconstituted extract
was injected into the LC-MS/MS system for quantitative
analysis.
LC-MS/MS Conditions LC was performed using an Agilent
1100 (Agilent Technologies, Waldbronn, Germany) LC sys-
tem. Chromatographic separation was carried out with a
Thermo Scient if ic BDS HYPERSIL C18 column
(100 × 3 mm I.D., 3-μm particle size). The advance column
with precolumn (10 × 3 mm I.D., 3-μm particle size) was set
at 40 °Cwith a mobile phase flow rate of 0.3 ml/min. Gradient
elution mobile phases consisted of formic acid (0.02 M) in
water (solvent A) and formic acid (0.02 M) in acetonitrile
(solvent B). The gradient began initially at 0% A during
1 min, increasing linearly to 90% at 2 min; this was main-
tained for 2 min and then was decreased to 0% at 6 min.
Finally, the last 4 min of the analysis remained at 100% B.
Sample temperature was maintained at 4 °C in the
autosampler prior to analysis. A sample volume of 10 μl
was injected into the analytical column for compound
analysis.
MS/MS analyses were accomplished on an Applied
Biosystems MDS Sciex (Concord, Ontario, Canada) API
2000 triple quadrupole mass spectrometer equipped with an
electrospray ionization (ESI) interface. ESI was performed in
the positive ionizationmode. A standard polypropylene glycol
solution (PPG standard) was used for instrument tuning and
mass calibration at unit mass resolution according to the
Applied Biosystems manual. The mass spectrometer was op-
erated with a dwell time of 200 ms. To find the optimal pa-
rameters of ion path and ion source of the studied compound,
the quantitative optimization was done by direct infusion of
standards using a Hamilton syringe pump (Hamilton, Reno,
NV, USA). Multiple reaction monitoring (MRM) mode of the
dominant product ion for each eCB was realized using the
optimal conditions. The ion source parameters were as fol-
lows: ion spray voltage (IS)—5500 V, nebulizer gas (gas
1)—30 psi, turbo gas (gas 2)—10 psi, temperature of the
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heated nebulizer (TEM)—400 °C, and curtain gas (CUR)—
25 psi. Comparison of pair ions (precursor and product ionm/z
values) and LC retention times with standards served to con-
firm the identification of eCB in the samples investigated. Ion
pairs were 348/62 for AEA, 379/287 for 2-AG, 352/66 for
AEA-d4, and 384/292 for 2-AG-d5. Data acquisition and pro-
cessing were accomplished using the Applied Biosystems
Analyst version 1.4.2 software.
Calibration Curve and Quantification The concentrations
of eCBs in the samples were calculated using the cali-
bration curve that was prepared on the same day and
analyzed in the same analytical run. Calibration curves
were constructed after analysis of the samples of brain
tissues collected from naïve rats. The homogenates were
spiked with AEA to the following concentrations: blank,
0.1, 1, 10, 25, 50, and 100 ng/g. For 2-AG, the follow-
ing solutions were used: blank, 0.4, 1, 5, 10, 25, and
50 μg/g. AEA-d4 and 2-AG-d5 were used as the internal
standards. The samples were analyzed according to the
procedure described above (BLipid Extraction from Brain
Tissue^ section).
Western Blot
Frozen brain structures were homogenized in buffer to the
homogenization (1 mM HEPES, 0.1 M DTT, 0.1 mM
EGTA (pH 7.2–7.8), COMPLETE, and sterile water) using a
homogenizer ball (Bioprep-24, Allsheng, China) (10 s at
10,000 rpm) and were then denatured for 2 min at 85 °C,
2 min in ice, 5 min at 85 °C, and finally 2 min in ice. For
protein determination, a bicinchoninic acid assay (BCA) pro-
tein assay kit (Serva, Germany) was used. Protein samples
(30 μg) were resolved by 10% SDS polyacrylamide gels and
transferred to a polyvinylidene difluoride (PVDF) membrane.
Membranes were blocked in 3% non-fat dry milk, and sepa-
rate sets of membranes were probed with rabbit anti-CB1
monoclonal antibody (1:800; ab172970; Abcam, UK;
Kaczocha et al. 2015), rabbit anti-CB2 polyclonal antibody
(1:500; 101550; Cayman, USA; Álvaro-Bartolomé and
García-Sevilla 2013), goat anti-NAPE-PLD polyclonal anti-
body (1:200; ab95397; Abcam, UK; Kaczocha et al. 2015),
goat anti-MAGL polyclonal antibody (1:200; ab24701;
Abcam, UK), rabbit anti-DAGLα polyclonal antibody
(1:200; ab81984; Abcam, UK), and mouse anti-FAAHmono-
c lona l an t ibody (1 :200; sc-100739; Santa Cruz
Biotechnology, USA). The expressions of CB1, CB2, NAPE-
PLD, FAAH, DAGLα, or MAGL were evaluated relative to
that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
using rabbit anti-GAPDH polyclonal antibody (1:1500, sc-
25778, Santa Cruz Biotechnology, USA). Blots were washed
and incubated with donkey anti-goat secondary antibody
(1:6000; 926-68074; Li-cor, USA), goat anti-rabbit secondary
antibody (1:6000; 926-68071; Li-cor, USA), or goat anti-
mouse (1:6000; 926-32210; Li-cor, USA) and visualized with
a fluorescence detection Odyssey Clx (Li-cor, USA). Analysis
was performed using Image Studio v.2.1. All data were
expressed as % of control.
Autoradiography
Consecutive coronal sections (12 μm) of rat brains were cut
on a cryostat microtome (Leica CM 1850, Germany) at
−22 ± 2 °C and were thaw-mounted on polylysine-coated
slides. Five coronal sections were mounted on a single slide
and stored at −80 °C. Receptor binding assay with
[3H]CP55,940 (PerkinElmer, USA; specific activity
164.5 Ci/mmol) was performed using the procedure described
previously with some modifications (Adamczyk et al. 2012).
The slices were preincubated for 2 h at 37 °C in buffer (con-
taining 50 mM Tris–HCl with 5% bovine serum albumin; pH
7.5).
Total binding was measured by incubating the appropri-
ate tissue sections with [3H]CP55,940 (2 nM) for 2 h at
37 °C in the buffer (see above). To determine the non-
specific binding, parallel sections were incubated addition-
ally in the presence of 10 μM CP55,940 (Sigma-Aldrich,
USA). Following the incubation period, tissue sections
were washed twice in an ice-cold (4 °C) buffer (containing
50 mM Tris–HCl with 1% bovine serum albumin; pH 7.5)
for 2 h and twice in distilled water (4 °C) for 1 min, and
then dried with cool air.
Radiolabeled, dried tissue sections were exposed to
tritium-sensitive screens (3H-Fujifilm imaging plates; Bas-
TR2025, Fuji Photo Film, Japan) for 10 days at 4 °C.
Induced autoradiograms were read out with a reader (BAS-
5000 IP Image Reader v.1.1, Fujifilm), and quantitative anal-
ysis was performed using the Fujifilm software (IMAGE
GAUGE, v.4.0.). Optical densities of gray values on the film
were converted into bound radioactivity with a polynomial
regression curve derived from autoradiographic
[3H]microscales (RPA 510, Amersham, UK) used as calibra-
tion markers. Data (fmol/mg tissue) are expressed as the
mean of the percentage of the control levels ± standard error
of mean (SEM).The binding signal was analyzed in several
brain areas, which were identified by comparing autoradio-
graphic images with appropriate figures from The Rat Brain
Atlas of Paxinos and Watson (1998) (Table 1).
Statistical Analyses
All data were expressed as the mean ± SEM. Statistical anal-
yses were performed with Student’s t test. P < 0.05 was con-
sidered statistically significant.
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Table 1 The obtain regions used for quantitative analysis, chosen according to The Rat Brain Atlas (Paxinos and Watson 1998). The color outlines
show the brain areas in which optical densities were quantified
A- Motor cortex (I–III layers)
A’- Motor cortex (IV–VI layers)
B- Prelimbic cortex (I–III layers)
B’- Prelimbic cortex (IV–VI layers)
C- Infralimbic cortex
D- Frontal cortex (II-III layers)
E- Frontal cortex (V layer)
F- Cingulate cortex
G- Laterodorsal striatum 
G’- Mediodorsal striatum 
H- Nucleus accumbens core 
H’- Nucleus accumbens shell 
I- Amygdaloid nuclei: basolateral (anterior, 
posterior and ventral parts) and basomedial
(posterior part)
J- Dentate gyrus (Hippocampus)- bregma -3.30
K- CA1 layer (Hippocampus)- bregma -3.30
L- CA2 layer (Hippocampus)- bregma -3.30
M- CA3 layer (Hippocampus)- bregma -3.30
N- Dentate gyrus (Hippocampus)- bregma -5.30
O- CA1 layer (Hippocampus)- bregma -5.30
P- CA2 layer (Hippocampus)- bregma -5.30
R- CA3 layer (Hippocampus)- bregma -5.30
S- Ventral tegmental area 
T- Substantia nigra
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Results
Behavioral Tests
FST
The OBX rats displayed longer (by 30.7%) (t = 3.652; df = 14;
p = 0.0026) immobility time compared with the SHAM con-
trols (OBX rats 140.5 ± 8.0; SHAM-operated rats
107.5 ± 4.1). The WKY rats demonstrated a significantly in-
creased (by 45.2%) (t = 2.614; df = 14; p = 0.0204) immobility
time compared with the control group (WKY rats
126.9 ± 10.3; Wistar rats 87.4 ± 11.1).
Locomotor Activity
Removal of the olfactory bulbs evoked a significant enhance-
ment of rat locomotor activity during 5-min (OBX rats
1714 ± 125; SHAM-operated rats 1132 ± 80; t = 3.929;
df = 14; p = 0.015) and 30-min (OBX rats 5042 ± 330;
SHAM-operated rats 3282 ± 333; t = 3.753; df = 14;
p = 0.0021) trials. The locomotor activity of the WKY rats
was unchanged compared with that of the control animals in
the 5-min (WKY rats 1085 ± 164; Wistar rats 1025 ± 78) or
30-min (WKY rats 2883 ± 48; Wistar rats 2468 ± 209) trials.
Biochemical Analyses
eCB Tissue Content
AEAWhen comparing the OBX to the SHAM rats (Fig. 2a),
we found a significant reduction of the AEA levels in the
prefrontal cortex (t = 4.487; df = 14; p = 0.0005), hippocam-
pus (t = 5.405; df = 14; p < 0.0001), and dorsal striatum
(t = 3.328; df = 14; p = 0.005). At the same time, removal of
the olfactory bulbs evoked a significant enhancement of the
AEA levels in the nucleus accumbens (t = 7.394; df = 14;
p < 0.0001) (Fig. 1a).
In the WKY rats, the levels of AEA either increased in the
prefrontal cortex (t = 5.499; df = 14; p < 0.0001) or decreased
in the dorsal striatum (t = 2.384; df = 14; p = 0.0318), while no
changes in the rest of the brain structures were observed
(Fig. 1a).
2-AG The 2-AG levels either increased in the prefrontal cor-
tex (t = 3.683; df = 14; p = 0.0025) or decreased in the nucleus
accumbens (t = 4.316; df = 14; p = 0.0007) in the OBX rats
compared with those in the SHAM-operated controls
(Fig. 1b).
In the WKY rats, a decrease in 2-AG levels was observed
in the prefrontal cortex (t = 4.715; df = 14; p = 0.0003)
(Fig. 1b).
Enzyme Protein Expression
NAPE-PLD and FAAH Removal of the olfactory bulbs in-
duced either a decrease in NAPE-PLD protein expression in
the prefrontal cortex (t = 3.001; df = 14; p = 0.0111) or an
increase in the expression of this protein in the nucleus ac-
cumbens (t = 2.754; df = 14; p = 0.0175) compared with
SHAM-operated rats (Fig. 2a). In the WKY rats, an increase
in NAPE-PLD protein expression was observed in the pre-
frontal cortex (t = 2.722; df = 14; p = 0.0185), and a decrease
of this protein expression was shown in the nucleus accum-
bens (t = 2.266; df = 14; p = 0.0427) (Fig. 2a).
In the OBX rats, an increase of FAAH protein expression
was seen in the prefrontal cortex (t = 3.058; df = 14;
p = 0.0099) and hippocampus (t = 2.887; df = 14;
p = 0.0137) (Fig. 2b). In the WKY rats, either an increase in
FAAH protein expression in the dorsal striatum (t = 3.209;
df = 14; p = 0.0075) or a decrease in this protein expression
in the nucleus accumbens (t = 2.255; df = 14; p = 0.0436) was
noted (Fig. 2b).
DAGLα and MAGL In the OBX rats, an increase of
DAGLα protein expression was noted in the prefrontal cortex
(t = 2.919; df = 14; p = 0.0129) compared with that in the
SHAM-operated rats, while in the WKY rats, the levels of
DAGLα protein expression did not change (Fig. 3a).
Removal of the olfactory bulbs in rats evoked a reduction
of MAGL protein expression in the prefrontal cortex
(t = 3.876; df = 14; p = 0.0022) and frontal cortex
(t = 4.994; df = 14; p = 0.0003), while in the nucleus accum-
bens, higher levels of MAGL protein expression were noted
(t = 4.151; df = 14; p = 0.0013) (Fig. 3b). In the WKY rats,
only a significant increase of MAGL protein expression was
seen in the prefrontal cortex (t = 3.073; df = 14; p = 0.0097)
(Fig. 3b).
CB1 Receptor Autoradiography
Differentiation of radioligand binding to the CB1 receptors
was dependent on the structure and was in the range of
40.40 ± 2.18 (frontal cortex layer II/III) to 384.10 ± 16.38
(substantia nigra) fmol/mg tissue in the control animals.
Low values of radioligand binding (40–60 fmol/mg tissue)
were seen in the motor cortex, prelimbic cortex, infralimbic
cortex, frontal cortex, nucleus accumbens, amygdala, and ven-
tral tegmental area; the mean values (between 70 and
110 fmol/mg tissue) were observed in the dorsal striatum
and hippocampal areas; and the maximum binding (greater
than 350 fmol/mg tissue) was observed in the substantia nigra.
In the OBX rats, the binding of [3H]CP55,940 either in-
creased in the prelimbic cortex (IV–VI layers) (t = 4.031;
df = 10; p = 0.0024) or decreased in the laterodorsal striatum
(t = 2.6; df = 10; p = 0.0265) compared with that in the
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SHAM-operated rats (Table 2). The binding of [3H]CP55,940
in the WKY rats increased in the motor cortex (I–III layers)
(t = 3.399; df = 10; p = 0.0068), motor cortex (IV–VI layers)
(t = 2.558; df = 10; p = 0.0285), prelimbic cortex (I–III layers)
(t = 5.07; df = 10; p = 0.0005), prelimbic cortex (IV–VI layers)
(t = 4.593; df = 10; p = 0.001), infralimbic cortex (t = 5.591;
df = 10; p = 0.0002), frontal cortex (II–III layers) (t = 4.967;
df = 10; p = 0.0006), frontal cortex (V layer) (t = 5.258;
df = 10; p = 0.0004), cingulate cortex (t = 3.146; df = 10;
p = 0.0104), laterodorsal striatum (t = 2.528; df = 10;
p = 0.03), nucleus accumbens core (t = 3.028; df = 10;
p = 0.0127), nucleus accumbens shell (t = 2.706; df = 10;
p = 0.0221), amygdala (t = 2.63; df = 10; p = 0.0252), dentate
gyrus of the hippocampus (t = 2.999; df = 10; p = 0.0134 and
t = 4.475; df = 10; p = 0.0012), and the hippocampal CA1
(t = 2.943; df = 10; p = 0.0147) and CA3 layers (t = 3517;
df = 10; p = 0,0056) compared with that in the Wistar rats
(Table 3).
CB1 and CB2 Receptor Expression
Removal of the olfactory bulbs evoked a decrease in CB1
receptor expression in the hippocampus (t = 2.994; df = 14;
p = 0.0112), dorsal striatum (t = 3.908; df = 14; p = 0.0021),
and nucleus accumbens (t = 2.648; df = 14; p = 0.0212)
(Fig. 4a). In the WKY rats, an increase of CB1 receptor ex-
pression was observed in the prefrontal cortex (t = 2.837;
df = 14; p = 0.015), hippocampus (t = 3.076; df = 14;
p = 0.0096), nucleus accumbens (t = 3.055; df = 14;
p = 0.01), and cerebellum (t = 2.692; df = 14; p = 0.0196)
(Fig. 4a).
In the OBX rats, a decrease of CB2 receptor expression was
noted in the prefrontal cortex (t = 2.857; df = 14; p = 0.0144)
and hippocampus (t = 2.988; df = 14; p = 0.0113), while in the
WKY rats, an increase of CB2 receptor expression was present
in the dorsal striatum (t = 2.396; df = 14; p = 0.0338) and
cerebellum (t = 3.13; df = 14; p = 0.0087) (Fig. 4b).
Discussion
The present results show that behavioral depressive-like be-
havior manifested by the increased immobility time in the FST
(without reduction in the locomotor activity) is paralleled by
several alterations in the eCB system components. We used
two models of depression utilizing completely different mech-
anisms for inducing a depressive phenotype. Removal of the
olfactory bulbs evokes behavioral, neurochemical, and immu-
nological changes, which are similar to alterations observed in
depressive patients (Kelly et al. 1997; Song and Leonard
2005; Wang et al. 2010; Jastrzebska et al. 2015) and are re-
versed by chronic treatment with antidepressants (Smaga et al.
2012; Yuan and Slotnick 2014). The other animal model of
depression, WKY rats, exhibits depressive-like behavior in
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Fig. 1 Changes in the eCBs levels; AEA (a) and 2-AG (b) in brain
structures from OBX and WKY rats. AEA anandamide, 2-AG 2-
arachidonoylglycerol, PFCTX prefrontal cortex, FCTX frontal cortex,
HIP hippocampus, DSTR dorsal striatum, NAc nucleus accumbens,
CER cerebellum, OBX bulbectomized rats, WKY Wistar Kyoto rats. All
data are expressed as mean ± SEM. N = 8 rats/group. *p < 0.05;
**p < 0.01; ***p < 0.001 vs SHAM-operated or Wistar rats
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the FST (Pare 1994; Armario et al. 1995; Lahmame and
Armario 1996; Rittenhouse et al. 2002) and open field test
(Pare 1994; Berton et al. 1997), together with abnormalities
in some central neurochemical-dopaminergic (Jiao et al. 2006)
and noradrenergic (Pardon et al. 2002) systems and hormonal
dysregulation of the HPA (Solberg et al. 2001), as well as
lower levels of brain-derived neurotrophic factor (BDNF) in
the CA3 region of the hippocampus (Malkesman and Weller
2009).
In our neurochemical analysis, the OBX rats showed re-
duced AEA levels and increased 2-AG levels in the prefrontal
cortex, while in the WKY rats, the cortical AEA levels were
increased and the 2-AG contents were significantly reduced.
The above data in the particular animal models of depression
are partly supported by human and animal studies in which
prefrontal eCB levels were either increased in alcoholic sui-
cide victims (Vinod et al. 2005) and in depressed suicide vic-
tims (Hungund et al. 2004) or reduced following exposure to
chronic unpredictable stress (CUS) (Hill et al. 2008a).
Additionally, clinical trials of untreated depressed patients
demonstrated changes in serum eCB levels that parallel the
changes seen in theWKY rats in our study. In fact, an increase
in the AEA level (Hill et al. 2008c; Ho et al. 2012) and a
decrease in the 2-AG level were observed in human female
patients with major depression (Hill et al. 2008c). It should be
noted that the WKY rats are a useful model that captures
specific functional domains relevant to clinical depression
and would seem most consistent with a melancholic depres-
sion profile showing severe symptoms of anxiety and depres-
sion (Willner and Belzung 2015). The WKY rats seem to be a
genetic model of childhood depression (Malkesman and
Weller 2009), while the OBX rats are more representative
for depression in adults.
Changes in the levels of eCBs observed in the prefrontal
cortex reflect the alteration in the expression of enzymes in-
volved in the metabolism of these compounds. Thus, an in-
crease in the levels of AEA in theWKY rats can result from an
increase in the expression of NAPE-PLD, which is the AEA
synthesizing enzyme, while a decrease in 2-AG levels in this
structure may be evoked by higher expression of MAGL, a 2-
AG degrading enzyme. Similar correlations were demonstrat-
ed in the OBX rats, where the reduction of AEA levels might
result from the reduced synthesis by NAPE-PLD or enhanced
degradation by FAAH. The increase in DAGLα expression
(enzyme synthesizing 2-AG) and the decrease in MAGL ex-
pression probably caused the increase in the levels of 2-AG in
the prefrontal cortex of the OBX rats. The above findings for
the first time show the importance of alterations in eCB
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Fig. 2 Changes in the expression of metabolizing enzymes of AEA
synthetizing enzyme—NAPE-PLD (a) and degrading enzyme—FAAH
(b) in brain structures from OBX and WKY rats. AEA anandamide,
NAPE-PLD N-acyl phosphatidylethanolamine phospholipase D, FAAH
fatty acid amide hydrolase, PFCTX prefrontal cortex, FCTX frontal cortex,
HIP hippocampus, DSTR dorsal striatum, NAc nucleus accumbens, CER
cerebellum,OBX bulbectomized rats,WKYWistar Kyoto rats. All data are
expressed as mean ± SEM. N = 8 rats/group. *p < 0.05; **p < 0.01 vs
SHAM-operated or Wistar rats
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metabolizing enzymes as a potential factor inducing changes
in the levels of eCBs in animal models of depression. These
data complement only one report in which the FAAH activity
was studied in the prefrontal cortex in rats subjected to the
CUS procedure (Hill et al. 2008a).
The increased AEA levels in the prefrontal cortex of the
WKY rats may be involved in reduction of 5-HTergic neuro-
transmission and in depression-like behavior. As shown in
these animals, increases in the AEA levels via activation of
CB1 receptors up-regulated 5-HT2A receptor activity while
concurrently down-regulating 5-HT1A receptor activity (Hill
et al. 2006). The latter neuroadaptations were observed in
depressed patients (Drevets et al. 1999; Bhagwagar et al.
2004). The rise of the AEA levels may also induce emotional
discomfort during depression and reinforce emotional memo-
ries of aversive stimuli (Morena et al. 2014). The activation of
the eCB system via CB1 receptors strongly modulates mem-
ory consolidation (Lafourcade et al. 2007). The latter changes
may be further enhanced by the increased CB1 receptor den-
sity in various brain areas in the WKY rats, such as in the
cortical areas, which was demonstrated in our study.
Furthermore, the increased expression of CB1 receptors in
the prefrontal cortex, seen in our study in the WKY rats and
in other various animal models of depression induced by stress
factors (Bortolato et al. 2007; Hill et al. 2008a; McLaughlin
et al. 2013), seems to be a common characteristic change for
this type of symptom. The elevated AEA levels also decreased
the concentration, metabolism, and physiological functions of
2-AG via vanilloid receptors (TRPV1) (Maccarrone et al.
2008; Bystrowska et al. 2014a), and reduced 2-AG levels
were seen in the prefrontal cortex in the WKY rats in our
study. To partly support the 2-AG significance in the prefron-
tal cortex, the antidepressant drug tranylcypromine, contrary
to the WKY rats, increased the 2-AG levels in the prefrontal
cortex (Hill et al. 2008b).
On the other hand, reduction of AEA levels in the prefron-
tal cortex in the present study following bulbectomy might be
associated with alterations in monoaminergic signaling. In
fact, in the OBX rats, the extracellular levels of dopamine
(Prins et al. 2010), 5-HT (van der Stelt et al. 2005;
Jastrzebska et al. 2015), and noradrenaline (Jastrzebska et al.
2015) were reduced in the prefrontal cortex. Homeostasis of
eCB signaling may remain stable due to up-regulation of the
2-AG levels (seen in this study) or/and of the CB1 receptor
density in the prefrontal cortex (Rodriguez-Gaztelumendi
et al. 2009). The increased CB1 receptor density was also
confirmed in our study, although this increase was demon-
strated only in the prelimbic cortex (IV–VI layers) using au-
toradiography, while labeling of proteins with specific anti-
bodies did not show changes in CB1 receptors, and even a
decrease in the CB2 receptor expression in the OBX rats was
observed. The reason for the differences in the levels of CB1
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Fig. 3 Changes in the expression of metabolizing enzymes of 2-AG
synthetizing enzyme—DAGLα (a) and degrading enzyme—MAGL (b)
in bra in s t ruc tu res f rom OBX and WKY ra t s . 2 -AG 2-
arachidonoylglycerol, DAGLα diacylglycerol lipase α, MAGL
monoacylglycerol lipase, PFCTX prefrontal cortex, FCTX frontal cortex,
HIP hippocampus, DSTR dorsal striatum, NAc nucleus accumbens, CER
cerebellum, OBX bulbectomized rats, WKY Wistar Kyoto rats. All data
are expressed as mean ± SEM. N = 8 rats/group. *p < 0.05; **p < 0.01;
***p < 0.001 vs SHAM-operated or Wistar rats
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receptors between the autoradiography andWestern blot study
is probably related to the internalization and trafficking of
these receptors (Coutts et al. 2001; Leterrier et al. 2004).
These molecular processes could explain the lack of changes
in the expression of CB1 receptors analyzed in homogenates
of the whole structure (membrane and endogenous receptors),
while changes were detected in the CB1 receptor density after
binding the tritiated agonist to the membrane receptors with
constitutive activity during the autoradiography. Furthermore,
the bulbectomy-induced increase in CB1-receptor signaling in
the prefrontal cortex was reversed by chronic fluoxetine ad-
ministration (Rodriguez-Gaztelumendi et al. 2009).
Our present findings also demonstrated a reduction in AEA
levels in the hippocampus in the OBX rats accompanied by
increased FAAH expression. AEA is metabolized primarily
by FAAH, and the reduced AEA levels may impair
neurogenesis in the hippocampus in the OBX rats. In fact, it
was reported that hippocampal neurogenesis was reduced in
depressed patients (Sheline et al. 1996) and in animal models
of depression (Toth et al. 2008) probably due to AEA-
mediated excitotoxic damage (Marsicano et al. 2003). In fact,
our previous study showed that hippocampal glutamate levels
are elevated in OBX rats (Jastrzebska et al. 2015).
Antidepressant-like effects have been demonstrated after acti-
vation of the eCB system in the hippocampus following either
FAAH inhibition (Bambico et al. 2010) or direct CB1 receptor
stimulation (McLaughlin et al. 2007). Altogether, the damp-
ened hippocampal eCB signaling seen in our study may pro-
voke the opposite, i.e., depression-like, effects. Our current
findings are strongly supported by studies using several ani-
mal models of depression based on stress (Hill et al. 2008a;
Dubreucq et al. 2012). In the present study, both down-
regulation of CB1 and CB2 receptors and a decrease in the
AEA level were present in the hippocampus after bulbectomy.
Administration of AEA for 5 days resulted in a significant
increase in CB1 receptor density in the hippocampus
(Romero et al. 1995), so moderate activation of CB1 receptor
activity can result in its up-regulation in the hippocampus,
while by analogy, a bulbectomy-induced decrease in AEA
level provokes the decrease in CB1 receptor density due to
withdrawal of a trophic factor (ligand) for CB1 receptor ex-
pression (Hill et al. 2005). Additionally, synthesis of eCBs is
Table 2 The binding of
[3H]CP55.940 to CB1 receptors in
various brain areas in OBX rats
SHAM OBX
Motor cortex (I–III layers) 100.0 ± 7.97 119.9 ± 8.08
Motor cortex (IV–VI layers) 100.0 ± 7.64 101.3 ± 5.68
Prelimbic cortex (I–III layers) 100.0 ± 10.56 92.1 ± 5.11
Prelimbic cortex (IV–VI layers) 100.0 ± 5.08 143.9 ± 9.63**
Infralimbic cortex 100.0 ± 10.10 95.8 ± 5.22
Frontal cortex (II–III layers) 100.0 ± 8.45 109.6 ± 4.49
Frontal cortex (V layer) 100.0 ± 12.07 101.3 ± 5.87
Cingulate cortex 100.0 ± 6.28 111.8 ± 5.20
Laterodorsal striatum 100.0 ± 5.93 82.1 ± 3.53*
Mediodorsal striatum 100.0 ± 4.80 103.1 ± 6.29
Nucleus accumbens core 100.0 ± 10.65 100.1 ± 9.58
Nucleus accumbens shell 100.0 ± 13.75 89.9 ± 9.20
Amygdala 100.0 ± 7.98 102.7 ± 5.38
Dentate gyrus (hippocampus)—bregma—3.30 100.0 ± 4.15 112.6 ± 6.53
CA1 layer (hippocampus)—bregma—3.30 100.0 ± 6.15 93.9 ± 7.20
CA2 layer (hippocampus)—bregma—3.30 100.0 ± 12.66 121.3 ± 13.64
CA3 layer (hippocampus)—bregma—3.30 100.0 ± 4.75 101.5 ± 11.83
Dentate gyrus (hippocampus)–bregma—5.30 100.0 ± 6.67 95.0 ± 1.71
CA1 layer (hippocampus)—bregma—5.30 100.0 ± 10.85 114.1 ± 4.68
CA2 layer (hippocampus)—bregma—5.30 100.0 ± 8.78 112.0 ± 10.76
CA3 layer (hippocampus)—bregma—5.30 100.0 ± 7.15 94.3 ± 7.37
Ventral tegmental area 100.0 ± 4.85 97.1 ± 8.15
Substantia nigra 100.0 ± 4.86 99.9 ± 5.95
The number of animals in all examined groups was n = 6. Data are presented as the mean percent binding
(±S.E.M.) relative to control (SHAM)
OBX bulbectomized rats, SHAM SHAM-operated rats
*p < 0.05; **p < 0.01 vs. SHAM
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Table 3 The binding of
[3H]CP55.940 to CB1 receptors in
various brain areas in WKY rats
WISTAR WKY
Motor cortex (I–III layers) 100.0 ± 3.37 117.4 ± 3.86**
Motor cortex (IV–VI layers) 100.0 ± 5.89 115.7 ± 1.78*
Prelimbic cortex (I–III layers) 100.0 ± 1.66 129.9 ± 5.66***
Prelimbic cortex (IV–VI layers) 100.0 ± 5.73 135.2 ± 5.08***
Infralimbic cortex 100.0 ± 2.36 123.5 ± 3.48***
Frontal cortex (II–III layers) 100.0 ± 7.61 138.5 ± 1.48***
Frontal cortex (V layer) 100.0 ± 7.45 148.5 ± 5.43***
Cingulate cortex 100.0 ± 7.23 128.9 ± 5.66*
Laterodorsal striatum 100.0 ± 6.72 120.5 ± 4.54*
Mediodorsal striatum 100.0 ± 4.96 110.5 ± 3.31
Nucleus accumbens core 100.0 ± 7.90 129.7 ± 5.83*
Nucleus accumbens shell 100.0 ± 5.67 126.2 ± 7.82*
Amygdala 100.0 ± 8.04 123.2 ± 3.66*
Dentate gyrus (hippocampus)—bregma—3.30 100.0 ± 4.73 128.8 ± 8.35*
CA1 layer (hippocampus)—bregma—3.30 100.0 ± 4.71 113.2 ± 5.69
CA2 layer (hippocampus)—bregma—3.30 100.0 ± 4.54 117.0 ± 8.53
CA3 layer (hippocampus)—bregma—3.30 100.0 ± 5.54 103.4 ± 9.02
Dentate gyrus (hippocampus)—bregma—5.30 100.0 ± 6.08 129.0 ± 2.21**
CA1 layer (hippocampus)—bregma—5.30 100.0 ± 4.52 135.6 ± 11.24*
CA2 layer (hippocampus)—bregma—5.30 100.0 ± 8.55 114.7 ± 11.53
CA3 layer (hippocampus)—bregma—5.30 100.0 ± 5.80 123.3 ± 3.18**
Ventral tegmental area 100.0 ± 13.07 124.9 ± 14.88
Substantia nigra 100.0 ± 8.00 100.7 ± 5.72
The number of animals in all examined groups was n = 6. Data are presented as the mean percent binding
(±S.E.M.) relative to control (Wistar)
WKY Wistar Kyoto rats
*p < 0.05; **p < 0.01; ***p < 0.001 vs. SHAM
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Fig. 4 Changes in the expression of CB receptors CB1 (a) and CB2 (b) in
brain structures from OBX and WKY rats. PFCTX prefrontal cortex,
FCTX frontal cortex, HIP hippocampus, DSTR dorsal striatum, NAc
nucleus accumbens, CER cerebellum, OBX bulbectomized rats, WKY
Wistar Kyoto rats. All data are expressed as mean ± SEM. N = 8
rats/group. *p < 0.05; **p < 0.01 vs SHAM-operated or Wistar rats
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modulated by changes in other neurotransmitter systems
(Smaga et al. 2014a, b), so it is difficult to speculate on the
exact mechanism of action of these physiological changes.
However, in opposition to Vinod et al. (2012), we did not
detect changes in the AEA level in the hippocampus in the
WKY rats. The reasons for these differences between the
present and Vinod et al. (2012) results are probably related
to the different conditions used during eCB detection.
Despite the lack of changes in the levels of endogenous li-
gands in this study, similar increases in the CB1 receptor ex-
pression and an increase in the density of these receptors in the
hippocampal dentate gyrus and CA1 and CA3 fields were
noted in the WKY rats (present study; Vinod et al. 2012).
Reduction in the AEA levels was also seen in the striatum in
both the OBX and WKY rats. The latter change seems to be
associated with a weaker hedonic response (anhedonia), a symp-
tom characteristic of a depressive state (Hill et al. 2008a). Several
studies have shown that attenuation of the striatal eCB signaling
provoked depressive-like behavior in stress-related models (i.e.,
CUS and chronic mild stress (CMS)) (Hill et al. 2008a; Reich
et al. 2013a, b; Segev et al. 2013) and in OBX rats (Eisenstein
et al. 2010), while several antidepressant drugs increased the
striatal AEA contents (Smaga et al. 2014a). The weakening of
the eCB signaling in the OBX rats was supported also by a
decrease in the density of CB1 receptors in the laterodorsal stri-
atum and by the lowered CB1 receptor expression in the dorsal
striatum. The data in the literature on rats with depressed pheno-
type (after CUS procedure) confirm our observations (Hill et al.
2008a). Interestingly, in contrast to bulbectomy-induced changes,
an increase in the CB1 receptor density in the laterodorsal stria-
tum together with up-regulation of CB2 receptors were observed
in this structure in the WKY rats.
The reduced AEA levels in this structure may be either
caused by the increased expression of FAAH seen in the
WKY rats (but not in the OBX rats) or may be related to the
decreased eCB release regulated by synaptic activity. In fact,
the level of neuronal firing modulates postsynaptic eCB re-
lease from postsynaptic neurons and long-term depression
(LTD) at both glutamatergic and GABAergic synapses in the
striatum (Adermark et al. 2009). Endogenous dopamine is
also involved in the generation of eCB-LTD by synaptic ac-
tivity via the striatal D2 receptors (Kreitzer and Malenka
2005), and in addition, altered dopaminergic neurotransmis-
sion has been shown to provoke anhedonia (Holmes 1999).
Bulbectomy induces an increase in dopamine release and D1
and D2 receptor gene expression in the striatum (Holmes
1999; Masini et al. 2004), while alterations of this neurotrans-
mitter evokes a decrease in the AEA release via D1 receptors
(Patel et al. 2003), which was also observed in the OBX rats in
the present study. Moreover, the increased locomotor activity
seen in this paper was probably related to up-regulated dopa-
mine release in the striatum, which was also confirmed in
another study (Masini et al. 2004).
The opposing regulation of AEA and 2-AG tissue contents
was observed in the rat nucleus accumbens, where the AEA
levels were elevated, while the 2-AG concentration decreased
after bulbectomy. Interestingly, expression of the AEA syn-
thesizing enzyme and the 2-AG degrading enzyme was in-
creased, which can explain the changes in the eCB levels in
the OBX rats. On the other hand, in the WKY rats, although
there was a decrease in the expression of the enzymes synthe-
sizing and degrading AEA, homeostasis of this mediator was
not compromised, and the AEA levels did not change in the
nucleus accumbens. Lack of changes in the levels of neuro-
transmitters, despite disturbances in metabolizing enzymes,
may be associated with a local increase in the density and
expression of CB1 receptors in the core and shell of the nucle-
us accumbens in the WKY rats.
Changes in the eCB levels in the nucleus accumbens in the
OBX rats seem to be closely related to alterations in other
brain neurotransmitters. eCBs are engaged in the LTD of glu-
tamatergic signaling in the nucleus accumbens. The gluta-
matergic synapses, where CB1 receptors are located, modulate
the firing of GABAergic neurons in the nucleus accumbens,
which in turn decreases the dopaminergic neurons of the ven-
tral tegmental area (VTA). eCBs may disinhibit dopamine
cells of the VTA by reducing the excitatory transmission in
the nucleus accumbens, increasing the dopamine firing rate,
and provoking dopamine release in the nucleus accumbens
(Robbe et al. 2001). In the OBX rats, it was shown that glu-
tamatergic and GABAergic neurotransmission was dysregu-
lated, which also led to the changes in the dopaminergic sys-
tem (Song and Leonard 2005; Jastrzebska et al. 2015).
Changes in the OBX rats were accompanied by reduced ex-
pression of CB1 receptors in the nucleus accumbens, but this
change does not seem to be related to the levels of neurotrans-
mitters. Additionally, several papers showed that AEA admin-
istration, an FAAH inhibitor or CB1 agonists evoked augmen-
tation of dopamine concentration in the nucleus accumbens
shell in rats (Hungund et al. 2003; Lecca et al. 2006; Solinas
et al. 2006; Cadoni et al. 2008) as well as self-administered 2-
AG stimulated dopamine release in the nucleus accumbens
shell in rats (De Luca et al. 2014).
Finally, changes in the eCB system were also detected in
the cerebellum only in the WKY rats, while no changes in the
eCB levels and in the expression of enzymes involved in their
metabolism were observed. In addition, an increase in the
expression of CB1 and CB2 receptors was noted in the cere-
bellum in the WKY rats. In naïve rats, the CB1 receptors are
strongly expressed on basket cells located in the cerebellar
cortex, where they form synapses on the cell bodies of
Purkinje cells and make inhibitory synapses with Purkinje
cells (Yoshida et al. 2002). Stimulation of the CB1 receptor
suppresses spontaneous inhibitory postsynaptic currents
(IPSCs) and is involved in the depolarization-induced sup-
pression of inhibition (DSI) by influencing the presynaptic
432 Neurotox Res (2017) 31:421–435
inhibitory terminals (Yoshida et al. 2002). The strengthened
eCB signaling by up-regulation of CB receptors, observed in
our study, can aggravate inhibitory signals from GABA ter-
minals in the cerebellum and induce a depression-like pheno-
type in the WKY rats.
Conclusion
In summary, the common change observed in both the genetic
(WKY) and bulbectomy-inducedmodels of depression entails
weakness of eCB signaling (AEA) in the dorsal striatum, what
can induce a characteristic symptom of depression, anhedonia.
In other brain structures, neurochemical changes were differ-
ent, and they seemed to be associated with the particular brain
structures and the factors inducing depression. For the first
time, our study showed changes in the CB2 receptor expres-
sion in several brain structures in animal models of depression
and the importance of alterations in eCB metabolizing en-
zymes as a potential factor inducing changes in eCB levels.
The changes in the eCB system observed in several rat brain
structures in different animal models of depression suggest a
complex role of this system in the pathogenesis of depression.
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